Dr. Zong Sheng Guo
BSc, PhD (Harvard)
Associate Professor, Surgical Oncology Research – UPMC Hillman Cancer Center
corporate_fareUPMC Hillman Cancer Center, Pittsburgh, USA
Zong Sheng Guo
BSc, PhD (Harvard)
Prof. Zong Sheng Guo, PhD, is a distinguished cancer research scientist and Associate Professor in the Department of Surgery at the University of Pittsburgh School of Medicine, with primary affiliation at UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania. With over 22 years of continuous research experience, he is recognised internationally as a leading expert in oncolytic virus immunotherapy, cancer gene therapy, and combination immunotherapy strategies for solid tumours.
Prof. Guo earned his BSc in Microbiology from Xiamen University and his PhD in Microbiology and Molecular Genetics from Harvard University before joining the University of Pittsburgh faculty in January 2002. Over two decades of research at UPMC, he has developed novel therapeutic strategies using oncolytic viruses — particularly vaccinia virus platforms — to treat melanoma, sarcoma, and gastrointestinal cancers. His landmark first-in-human Phase I study of oncolytic vaccinia virus (vvDD) demonstrated clinical safety and antitumour activity, opening the pathway for combination approaches with checkpoint inhibitors. With over 200 peer-reviewed publications, more than 10,000 citations, and an h-index of 52, Prof. Guo is one of the most impactful researchers in the oncolytic virotherapy field globally. He also serves as a China–USA scientific bridge, given his academic roots in China and his leading position at one of America's premier cancer centres.
Prof. Guo's academic background in China and his leadership at UPMC make him a significant point of reference for patients and institutions exploring oncolytic virus therapy across Asia and internationally. CancerFax can coordinate second-opinion submissions and research-access enquiries.
Why Consider Prof. Zong Sheng Guo?
Prof. Guo is among the world's foremost researchers in oncolytic virus cancer therapy. His decades of translational research at UPMC Hillman Cancer Center have produced clinical results that are directly shaping the next generation of cancer immunotherapy.
Research Specialisations
Translational oncology research in oncolytic virotherapy, cancer immunotherapy, and gene therapy
Prof. Guo's research portfolio covers the full translational arc from laboratory discovery to Phase I clinical application, with a focus on using oncolytic viruses to selectively destroy cancer cells while inducing durable antitumour immune responses.
Oncolytic Virotherapy
Engineering and deploying oncolytic viruses to selectively infect, replicate within, and destroy tumour cells while triggering systemic anticancer immunity.
- arrow_rightDesign and preclinical evaluation of tumour-selective vaccinia virus platforms
- arrow_rightFirst-in-human Phase I intravenous vvDD trial in advanced solid cancers
- arrow_rightCarrier cell-mediated delivery strategies to enhance tumour targeting
- arrow_rightT-cell engager-armed oncolytic virus constructs
- arrow_rightViral replication selectivity in solid tumour microenvironments
- arrow_rightT-VEC and related herpesvirus-based platform research
Combination Cancer Immunotherapy
Rationally designed combinations of oncolytic viruses with checkpoint blockade and adoptive cell therapies to achieve synergistic antitumour responses.
- arrow_rightOncolytic vaccinia virus combined with PD-L1 blockade (Nature Communications 2017)
- arrow_rightEpigenetic modulation to enhance checkpoint inhibitor efficacy (Molecular Cancer 2021)
- arrow_rightPreclinical and translational combination protocols for melanoma and sarcoma
- arrow_rightIn vivo priming of tumour-reactive lymphocytes via oncolytic virus platforms
- arrow_rightCAR-T cell therapy research in combination with viral immunotherapy
- arrow_rightImmunogenic cell death induction as a driver of antitumour T-cell responses
Cancer Gene Therapy & Epigenetics
Gene therapy strategies and epigenetic reprogramming approaches to sensitise tumours to immunological attack.
- arrow_rightGene-modified immune cell strategies for solid tumour treatment
- arrow_rightTherapeutic cancer vaccine development
- arrow_rightMolecular mechanisms of tumour-selective virus replication
- arrow_rightEpigenetic modulation of antitumour immunity
- arrow_rightSensitisation of immunologically cold tumours to checkpoint inhibition
- arrow_rightIntegration of epigenetic agents in combination immunotherapy protocols
Research Procedures & Clinical Contributions
Translational research procedures and Phase I clinical trial contributions
Prof. Guo's clinical research contributions span Phase I trial design and execution, preclinical model development, and translational immunotherapy protocols. The following represents his research and clinical trial scope rather than direct patient treatment.
Oncolytic Virus Clinical Trials
Medical OncologyPhase I clinical trial leadership investigating intravenous oncolytic poxvirus platforms in patients with advanced solid cancers.
Combination Immunotherapy Research
Targeted TherapyRational combination of oncolytic viruses with checkpoint blockade and adoptive cell therapies in preclinical and translational models.
Translational Research & Second Opinion
Second OpinionResearch consultations and scientific second opinions for institutions and clinicians evaluating oncolytic virus therapy strategies.
Multidisciplinary Oncology Collaboration
MultidisciplinaryCollaboration with surgical oncologists and clinical investigators at UPMC Hillman Cancer Center on tumour immunology and virotherapy.
Research & Publications
Over 200 peer-reviewed publications with 10,000+ citations and Phase I clinical trial leadership
Prof. Guo's research output spans more than two decades and represents foundational contributions to the field of oncolytic virotherapy and combination cancer immunotherapy. He has been Principal or Co-Investigator on multiple Phase I clinical trials and serves as editorial leader for specialised Frontiers journal issues.
Prof. Guo's research profile (200+ publications, h-index 52, 10,000+ citations) makes him one of the most cited researchers in oncolytic virus immunotherapy globally. CancerFax can coordinate research consultation and second-opinion access for patients and institutions exploring this modality.
Education & Training
Prof. Guo trained in microbiology in China before completing doctoral studies at Harvard University, followed by a research career spanning over two decades at the University of Pittsburgh School of Medicine.
Clinical Experience
Prof. Guo has spent over 22 years at the University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, building one of the most productive translational research programmes in oncolytic virus immunotherapy in the United States. Prior to joining UPMC, he held a research position at Roswell Park Comprehensive Cancer Center.
Languages & International
Prof. Guo conducts research consultations and communications in the following languages.
Prof. Guo communicates in both English and Mandarin, making research consultation and case discussion directly accessible to Chinese-speaking patients and institutions. CancerFax can facilitate this access.
CancerFax can coordinate professional medical interpreter support for additional languages when required.
How CancerFax Helps You Access Dr. Zong Sheng Guo
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Zong Sheng Guo's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Zong Sheng Guo's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Zong Sheng Guo before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Zong Sheng Guo's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Zong Sheng Guo's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Zong Sheng Guo's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Zong Sheng Guo
Prof. Guo is a research scientist specialising in oncolytic virus immunotherapy, cancer gene therapy, and combination immunotherapy. His work focuses on developing oncolytic virus platforms — particularly vaccinia virus — that selectively infect and destroy cancer cells while triggering durable antitumour immune responses. He has published over 200 peer-reviewed papers with more than 10,000 citations in this field.
Prof. Guo holds a PhD rather than an MD and works primarily as a cancer research scientist at UPMC Hillman Cancer Center. He is not a clinical treating physician. Patients seeking active cancer treatment should consult with clinical oncologists at UPMC or through the CancerFax patient navigation team. However, research consultations, second opinions on oncolytic virus therapy strategies, and clinical trial eligibility enquiries can be coordinated through CancerFax.
Prof. Guo's research focuses primarily on melanoma, sarcoma, and gastrointestinal cancers including colorectal cancer and hepatocellular carcinoma. His preclinical and translational studies have also covered head and neck cancer, glioma, breast cancer, peritoneal carcinomatosis, and multiple myeloma in the context of oncolytic virus therapy.
Oncolytic virus therapy uses specially engineered viruses that selectively infect and destroy cancer cells while simultaneously triggering the immune system to attack the tumour. Prof. Guo's group has led Phase I clinical trials of intravenous oncolytic vaccinia virus (vvDD) at UPMC. Access to this therapy for patients is currently through clinical trials. CancerFax can help assess whether a patient may be eligible for open trials at UPMC Hillman Cancer Center or other centres researching this approach.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review the case, assess whether a research consultation or second opinion related to oncolytic virus therapy is appropriate, and coordinate the next steps. This is subject to Prof. Guo's availability and the nature of the case.
A research consultation or second opinion request related to oncolytic virus therapy can be submitted through CancerFax with the patient's pathology reports, imaging, molecular profiling results, and treatment history. The format and availability of such consultations depend on Prof. Guo's schedule and institutional arrangements. CancerFax will facilitate this coordination and advise on realistic timelines.
Yes. Prof. Guo is a Chinese-American scientist who communicates in both English and Mandarin. His academic background in China and his leadership position at UPMC make him a meaningful bridge for Chinese patients and oncology institutions seeking access to oncolytic virus therapy expertise in the United States. CancerFax actively facilitates this China–USA oncology corridor.
Connect with Zong Sheng Guo Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.